Evidence map›Paper›PMID 29055736›Full record

ArticleThe Lancet. Oncology2017

Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.

Martin C Tammemagi, Heidi Schmidt, Simon Martel, Annette McWilliams, John R Goffin, Michael R Johnston, Garth Nicholas, Alain Tremblay, Rick Bhatia, Geoffrey Liu and 39 more

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in The Lancet. Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00751660 (Early Detection of Lung Cancer - A Pan Canadian Study), which is not on this map. Cited by 112 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00751660 naunknown statusnot on this map

Early Detection of Lung Cancer - A Pan Canadian Study

TypeinterventionalSponsorBritish Columbia Cancer AgencyRan2008Enrolled2,504ConditionsLung Cancer, Tobacco Use DisorderArmslaboratory biomarker analysis, screening questionnaire administration, bronchoscopic and lung imaging studies, computed tomography, endoscopic biopsy
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Knowledge translation strategies to enhance lung cancer screening programme implementation: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Lung cancer screening primer: Key information for primary care providers.Canadian family physician Medecin de famille canadien · 2021
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. A Noninvasive Circulating Tumor DNA Methylation Classifier to Identify Benign Pulmonary Nodules.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

49 authors.

Martin C TammemagiDepartment of Health Sciences, Brock University, St Catharines, ON, Canada.
Heidi SchmidtUniversity Health Network Toronto, ON, Canada.
Simon MartelInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Québec City, QC, Canada.
Annette McWilliamsFionna Stanley Hospital and Sir Charles Gairdner Hospital, Perth, WA, Australia.
John R GoffinJuravinski Cancer Centre, Hamilton, ON, Canada.
Michael R JohnstonDalhousie University, Halifax, NS, Canada.
Garth NicholasOttawa Hospital Cancer Centre, Ottawa, ON, Canada.
Alain TremblayUniversity of Calgary, Calgary, AB, Canada.
Rick BhatiaMemorial University, Newfoundland, NL, Canada.
Geoffrey LiuUniversity Health Network Toronto, ON, Canada.
Kam SoghratiUniversity Health Network Toronto, ON, Canada.
Kazuhiro YasufukuUniversity Health Network Toronto, ON, Canada.
David M HwangUniversity Health Network Toronto, ON, Canada.
Francis LabergeInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Québec City, QC, Canada.
Michel GingrasInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Québec City, QC, Canada.
Sergio PasianInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Québec City, QC, Canada.
Christian CoutureInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Québec City, QC, Canada.
John R MayoVancouver General Hospital, Vancouver, BC, Canada.
Paola V Nasute FauerbachQueen's University, Kingston, ON, Canada.
Sukhinder Atkar-KhattraBritish Columbia Cancer Agency, Vancouver, BC, Canada.
Stuart J PeacockBritish Columbia Cancer Agency, Vancouver, BC, Canada.
Sonya CressmanBritish Columbia Cancer Agency, Vancouver, BC, Canada.
Diana IonescuBritish Columbia Cancer Agency, Vancouver, BC, Canada.
John C EnglishVancouver General Hospital, Vancouver, BC, Canada.
Richard J FinleyVancouver General Hospital, Vancouver, BC, Canada.
John YeeVancouver General Hospital, Vancouver, BC, Canada.
Serge PuksaJuravinski Cancer Centre, Hamilton, ON, Canada.
Lori StewartJuravinski Cancer Centre, Hamilton, ON, Canada.
Scott TsaiJuravinski Cancer Centre, Hamilton, ON, Canada.
Ehsan HaiderSt Joseph's Healthcare, Hamilton, ON, Canada.
Colm BoylanSt Joseph's Healthcare, Hamilton, ON, Canada.
Jean-Claude CutzJuravinski Cancer Centre, Hamilton, ON, Canada.
Daria ManosDalhousie University, Halifax, NS, Canada.
Zhaolin XuDalhousie University, Halifax, NS, Canada.
Glenwood D GossOttawa Hospital Cancer Centre, Ottawa, ON, Canada.
Jean M SeelyOttawa Hospital Cancer Centre, Ottawa, ON, Canada.
Kayvan AmjadiOttawa Hospital Cancer Centre, Ottawa, ON, Canada.
Harmanjatinder S SekhonOttawa Hospital Cancer Centre, Ottawa, ON, Canada.
Paul BurrowesUniversity of Calgary, Calgary, AB, Canada.
Paul MacEachernUniversity of Calgary, Calgary, AB, Canada.
Stefan UrbanskiUniversity of Calgary, Calgary, AB, Canada.
Don D SinSt Paul's Hospital, Vancouver, BC, Canada.
Wan C TanSt Paul's Hospital, Vancouver, BC, Canada.
Natasha B LeighlUniversity Health Network Toronto, ON, Canada.
Frances A ShepherdUniversity Health Network Toronto, ON, Canada.
William K EvansJuravinski Cancer Centre, Hamilton, ON, Canada.
Ming-Sound TsaoUniversity Health Network Toronto, ON, Canada.
Stephen LamVancouver General Hospital, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada. Electronic address: slam2@bccancer.bc.ca.
PanCan Study Team

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResults from retrospective studies indicate that selecting individuals for low-dose CT lung cancer screening on the basis of a highly predictive risk model is superior to using criteria similar to those used in the National Lung Screening Trial (NLST; age, pack-year, and smoking quit-time). We designed the Pan-Canadian Early Detection of Lung Cancer (PanCan) study to assess the efficacy of a risk prediction model to select candidates for lung cancer screening, with the aim of determining whether this approach could better detect patients with early, potentially curable, lung cancer.

methodsWe did this single-arm, prospective study in eight centres across Canada. We recruited participants aged 50-75 years, who had smoked at some point in their life (ever-smokers), and who did not have a self-reported history of lung cancer. Participants had at least a 2% 6-year risk of lung cancer as estimated by the PanCan model, a precursor to the validated PLCOm2012 model. Risk variables in the model were age, smoking duration, pack-years, family history of lung cancer, education level, body-mass index, chest x-ray in the past 3 years, and history of chronic obstructive pulmonary disease. Individuals were screened with low-dose CT at baseline (T0), and at 1 (T1) and 4 (T4) years post-baseline. The primary outcome of the study was incidence of lung cancer. This study is registered with ClinicalTrials.gov, number NCT00751660.

findings7059 queries came into the study coordinating centre and were screened for PanCan risk. 15 were duplicates, so 7044 participants were considered for enrolment. Between Sept 24, 2008, and Dec 17, 2010, we recruited and enrolled 2537 eligible ever-smokers. After a median follow-up of 5·5 years (IQR 3·2-6·1), 172 lung cancers were diagnosed in 164 individuals (cumulative incidence 0·065 [95% CI 0·055-0·075], incidence rate 138·1 per 10 000 person-years [117·8-160·9]). There were ten interval lung cancers (6% of lung cancers and 6% of individuals with cancer): one diagnosed between T0 and T1, and nine between T1 and T4. Cumulative incidence was significantly higher than that observed in NLST (4·0%; p<0·0001). Compared with 593 (57%) of 1040 lung cancers observed in NLST, 133 (77%) of 172 lung cancers in the PanCan Study were early stage (I or II; p<0·0001).

interpretationThe PanCan model was effective in identifying individuals who were subsequently diagnosed with early, potentially curable, lung cancer. The incidence of cancers detected and the proportion of early stage cancers in the screened population was higher than observed in previous studies. This approach should be considered for adoption in lung cancer screening programmes.

fundingTerry Fox Research Institute and Canadian Partnership Against Cancer.

Indexed as

Patient SelectionAgedAge DistributionArea Under CurveCanadaCohort StudiesEarly Detection of CancerFemaleHumansIncidenceLung NeoplasmsMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPredictive Value of Tests

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.